Innovative Nanozymes Cross the Blood-Brain Barrier to Combat Parkinson’s Disease

Researchers have developed chiral nanozyme-based therapies that effectively traverse the blood-brain barrier, mitigate neuroinflammation, and improve Parkinson’s symptoms in preclinical models.

Key Highlights:

1. Research Question
Can chiral nanozymes integrated into metal-organic frameworks effectively cross the blood-brain barrier to alleviate oxidative stress and neuroinflammation in Parkinson’s disease?

2. Research Difficulties
The study addressed critical challenges, including stabilizing nanozyme systems to prolong blood circulation, enhancing their ability to cross the blood-brain barrier (BBB) via dual endocytosis pathways, and combating oxidative stress and neuroinflammation—key factors in Parkinson’s progression.

3. Key Findings
The researchers discovered that Ptzyme@D-ZIF nanozymes demonstrate superior blood-brain barrier traversal and brain accumulation compared to their L-chiral counterparts. These nanozymes effectively mitigated oxidative stress and neuroinflammation, reducing behavioral deficits and neuronal damage in Parkinson’s mouse models.

4. Innovative Aspects
• Dual-pathway BBB transcytosis leveraging chiral-dependent mechanisms.
• Enhanced enzymatic activity and ROS/RNS scavenging due to chiral modifications.
• Prolonged plasma stability and reduced immune clearance of Ptzyme@D-ZIF.

5. Importance of the Study
The findings offer a novel therapeutic avenue for addressing unmet needs in Parkinson’s treatment, paving the way for advanced neuroprotective therapies capable of crossing the BBB and targeting neuroinflammation.

—————————————————————————————————————————————————-

Parkinson’s Disease: Challenges and Current Treatments

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor dysfunction, memory impairment, and dopamine loss in the substantia nigra pars compacta. Oxidative stress and neuroinflammation are pivotal in the disease’s progression, contributing to neuronal apoptosis and ferroptosis. Current treatments, such as levodopa and dopamine agonists, aim to alleviate symptoms but fail to halt or reverse the disease’s progression. These limitations underscore the urgency of innovative therapeutic strategies that address the underlying pathophysiology.

Advancing Nanozyme Therapies for Parkinson’s Disease

The primary objective of this study was to develop chiral nanozyme-integrated metal-organic frameworks (MOFs) that traverse the blood-brain barrier (BBB) and target neuroinflammation in Parkinson’s disease. Conducted by researchers from Zhengzhou University and the Chinese Academy of Sciences, this investigation represents a multidisciplinary approach to tackling the challenges of BBB permeability and targeted therapy. The findings were published in Nature Communications in November 2023.

Designing and Testing Chiral Nanozymes

Experimental Process Outline:

1. Synthesis of ultra-small platinum nanozymes (Ptzymes) on a polymer template.
2. Encapsulation of Ptzymes into zeolitic imidazolate frameworks (ZIF) to create Ptzyme@ZIF.
3. Modification with chiral amino acids (L-histidine and D-histidine) to produce Ptzyme@L-ZIF and Ptzyme@D-ZIF.
4. Evaluation of enzyme-like activities and ROS/RNS scavenging in vitro.
5. Analysis of BBB traversal using in vitro and in vivo models.
6. Behavioral and pathological assessments in Parkinson’s mouse models.

Key Experiments and Results: 

1. Synthesis and Characterization of Chiral Nanozymes: Ultra-small Ptzymes were synthesized and encapsulated within ZIFs using a biomimetic mineralization approach. Chiral modification with histidine derivatives resulted in Ptzyme@L-ZIF and Ptzyme@D-ZIF. These nanozymes exhibited uniform size distributions (approximately 70 nm) and maintained structural integrity. In vitro enzymatic assays demonstrated their ability to mimic superoxide dismutase (SOD) and catalase (CAT) activities, with Ptzyme@D-ZIF showing enhanced activity.
2. BBB Transcytosis and Brain Accumulation: Ptzyme@D-ZIF demonstrated superior BBB traversal in an in vitro co-culture model of endothelial and neuronal cells. This was corroborated in vivo, where Ptzyme@D-ZIF exhibited a 2.20% ID/g brain accumulation compared to 1.42% for Ptzyme@L-ZIF. Dual endocytosis pathways—clathrin- and caveolae-mediated—enabled this enhanced transcytosis.
3. Therapeutic Efficacy in Parkinson’s Mouse Models: Behavioral assessments (Morris water maze, rotarod, and pole tests) revealed significant improvements in motor function and memory in mice treated with Ptzyme@D-ZIF. Pathological analysis showed reductions in neuroinflammation markers (GFAP and Iba-1) and oxidative stress (ROS and MDA levels). Dopaminergic neuron density in the substantia nigra pars compacta was restored to near-normal levels, as evidenced by increased tyrosine hydroxylase (TH) expression.

Summary — Implications for Neuroprotective Therapies

This study highlights the successful design and application of Ptzyme@D-ZIF nanozymes for addressing neuroinflammation and oxidative stress in Parkinson’s disease. The innovative integration of chiral-dependent BBB transcytosis pathways and enhanced antioxidant activity represents a significant advancement in neuroprotective therapies. The research provides a foundation for clinical translation but acknowledges challenges, such as long-term safety and optimization for human applications, which require further investigation.

Reference:
Jiang, Wei, et al. “Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson’s disease.” Nature Communications 14.1 (2023): 8137.